Sermorelin is a promising therapeutic for treatment-resistant recurrent glioma, especially high-grade, IDH-wildtype tumors
Background
Treatment insensitivity is the primary challenge in managing glioma, a type of brain tumor. While primary gliomas have established treatment protocols, recurrent gliomas often become resistant to therapy, leading to poor prognoses. This necessitates the discovery of novel therapeutic agents that can overcome this resistance. Current research is exploring ways to identify effective drugs for these specific, hard-to-treat patient populations. This study leveraged large-scale transcriptomics data to screen thousands of existing drugs, aiming to pinpoint compounds that could be repurposed for recurrent glioma, specifically targeting the molecular subtypes that are most aggressive, such as IDH-wildtype tumors.
Study Design
This was a computational drug screening study using existing patient data. Researchers analyzed transcriptome sequencing and clinical data from a total of 1,018 glioma patients. The cohort was split into a discovery group (n=325, with 92 recurrent cases) and a validation group (n=693, with 271 recurrent cases). They used a Drug Resistant Scores (DRS) model to evaluate the potential efficacy of 4,865 different drugs for each patient. The analysis, conducted using the R programming language, aimed to identify drugs to which recurrent glioma patients were most sensitive.
Results
High-throughput computational screening identified sermorelin as the drug to which recurrent glioma patients were most sensitive. This sensitivity was particularly pronounced in patients with specific aggressive tumor characteristics. The analysis revealed that sermorelin was most suitable for recurrent patients with high-grade tumors, an IDH-wildtype genetic status, and a 1p/19q non-codeletion status. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses suggested sermorelin's potential mechanism of action. The compound appears to inhibit tumor cell proliferation by inducing cell cycle blocking.
Furthermore, sermorelin was found to be linked to the immune system, negatively regulating immune checkpoints and M0 macrophages, suggesting it may enhance the body's anti-tumor immune response. A Kaplan-Meier survival analysis indicated that the potential benefits of sermorelin were independent of whether patients received postoperative adjuvant treatments.
Key Findings
- Out of 4,865 drugs screened, recurrent glioma patients were most sensitive to sermorelin.
- Sermorelin was most effective for high-grade, IDH-wildtype, and 1p/19q non-codeletion gliomas.
- Pathway analysis suggests sermorelin may inhibit tumor proliferation via cell cycle blocking.
- Sermorelin was linked to enhanced immune response via negative regulation of immune checkpoints and M0 macrophages.
- The potential survival benefit from sermorelin was independent of postoperative adjuvant therapy.
Why It Matters
This study proposes sermorelin as a potential new therapeutic avenue for recurrent glioma, one of the most difficult-to-treat cancers. For patients and clinicians dealing with aggressive, relapsed brain tumors—particularly the IDH-wildtype subtype—this offers a novel, data-driven hypothesis for treatment. While this is a computational study based on genetic data, it provides a strong rationale for moving sermorelin into preclinical and eventually clinical trials for this specific indication. The key implication is that an existing peptide therapeutic, sermorelin, could be repurposed to simultaneously suppress tumor growth and boost anti-cancer immunity in glioma patients who have exhausted standard options. This work lays the foundation for future studies to determine optimal dosing and combination therapies.
sermorelin
glioma
cancer
brain tumor
oncology
computational study
